As global drug giants grow cautious, can Chinese biotech keep cashing in on out-licensing?
Chinese biotech firms are increasingly relying on out-licensing deals with global partners for funding, surpassing IPOs. While these deals have been record-breaking, multinational drugmakers are signaling tighter budgets, raising questions about the sustainability of this…
Intelligence analysis by Gemini 2.5 Flash
Chinese biotech companies have found a new primary funding source in out-licensing deals with global pharmaceutical giants, which have seen record growth. However, this reliance faces potential challenges as major drugmakers indicate a more cautious approach to deal-making, prompting concerns about the long-term viability of this strategy for Chinese firms.
Chinese medicine companies are getting money by letting bigger global companies use their new drug ideas, which has been working really well. But now, the big companies might not want to spend as much, so the Chinese companies need to figure out how to keep getting money for their cool new medicines.
Analysis
US$110 billion
Chinese biotech firms experienced a remarkable surge in cross-border out-licensing deals during the first half of the year, with agreements for innovative drugs reaching an unprecedented US$110 billion. This figure represents a significant milestone, highlighting the growing global interest in China's pharmaceutical innovation. The volume of these agreements, totaling 81 deals, constituted approximately 80 percent of the previous year's entire deal count, underscoring the rapid acceleration of this funding model.
This substantial influx of capital has been transformative for many Chinese drug makers, enabling some previously loss-making companies to achieve profitability. The shift towards out-licensing as a primary financial lifeline indicates a strategic pivot away from traditional funding avenues like initial public offerings (IPOs) and pre-IPO fundraising. This reliance on overseas partnerships is crucial for advancing the complex and costly stages of drug discovery, clinical development, and regulatory approval.
Cui Cui
Cui Cui, head of healthcare research for Asia at Jefferies, offers a nuanced perspective on the evolving landscape of Chinese biotech funding. She emphasizes that Chinese biotech assets maintain a competitive edge due to their high cost-effectiveness when compared to their global counterparts. This inherent advantage could become even more pronounced if major pharmaceutical companies adopt a more selective approach to their acquisition spending.
According to Cui Cui, a scenario where global drug giants tighten their deal budgets might paradoxically make Chinese biotech assets appear even more attractive. This is because their relative affordability could offer a compelling value proposition for multinational corporations seeking innovation amidst financial constraints. Her analysis suggests that while the overall deal environment might become more challenging, the fundamental economic appeal of Chinese biotech could help sustain interest and investment.
Macquarie Capital
Tony Ren, head of Asia healthcare research at Macquarie Capital, further contextualizes the scale of China's out-licensing success by comparing it to traditional fundraising methods. He notes that the US$110 billion generated from cross-border deals is "quite sizeable" when juxtaposed with the proceeds from IPOs. This comparison highlights the profound impact out-licensing has had on the financial health and growth trajectory of Chinese biotech.
For instance, healthcare and drug companies collectively raised HK$14.1 billion (US$1.8 billion) through 11 Hong Kong listings in the first half, while six biotech and healthcare firms on mainland China's A-share market raised 2.12 billion yuan. These figures, while substantial in their own right, pale in comparison to the capital secured through out-licensing agreements. Ren's observation reinforces the idea that out-licensing has not just supplemented but largely supplanted other funding mechanisms for many Chinese biotech innovators.
Key points
- Out-licensing deals have become the primary funding source for Chinese biotech, surpassing IPOs.
- Cross-border deals for innovative drugs from China reached a record US$110 billion in the first half of the year.
- Multinational drugmakers are signaling plans to tighten their deal budgets.
- Analysts question the long-term sustainability of Chinese biotech's reliance on overseas licensing income.
- Chinese biotech assets are considered cost-effective compared to global peers.
Chinese biotech assets are considered highly cost-effective, which could make them even more attractive to global pharmaceutical companies if budgets tighten, potentially leading to continued deal flow despite increased selectivity. This could ensure a steady stream of funding for innovative drug development.
A tightening of deal budgets by multinational drugmakers could significantly reduce the out-licensing income that Chinese biotech firms have come to rely on, potentially stifling their ability to fund crucial drug discovery, clinical development, and regulatory approval processes. This reliance on overseas licensing might prove unsustainable if global partners become too cautious.
